Related Experiment Video
Updated: May 11, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Saline-based modified del Nido cardioplegia versus multidose St. Thomas cardioplegia in canine mitral valve repair: A
Kentaro Kurogochi1,2, Arane Takahashi1, Yasuyuki Nii1
1JASMINE Veterinary Cardiovascular Medical Center, Yokohama, Japan.
Objective:
To compare the utility of a saline-based modified del Nido (mDN) cardioplegia solution with a conventional institutional technique (multidose St. Thomas blood cardioplegia) for mitral valve repair (MVR) in dogs.
Study Design:
Prospective, randomized, open-label trial.
Animals:
Forty client-owned dogs with myxomatous mitral valve disease (stage B2 and C) eligible for MVR were divided into control and modified mDN groups.
Methods:
Cardioplegia was induced in the control group using 50% blood containing St. Thomas solution every 10 min. In the mDN group, a cardioplegia solution containing 20% blood was administered once or when required. As the primary outcome, serum cardiac troponin I levels were compared 12 h postoperatively between the groups. The other clinical findings were evaluated as secondary outcomes.
Results:
Troponin levels 12 h after surgery were a median of 27.8 ng/mL (interquartile range, 15.1-43.2) in the control group and 19.4 ng/mL (15.2-33.6) in the mDN group (p = .478). The sinus rhythm recovery time following aortic cross-clamp removal was 362 s (103-995) in the control group and 60 s (44-605) in the mDN group (p = .027). The total amount of crystalloid cardioplegia solution required was 12.6 mL/kg (11.3-15.0) in the control group and 23.6 mL/kg (18.0-35.1) in the mDN group (p < .001).
Conclusion:
Cardiac troponin I levels did not show differences between the groups. The saline-based mDN cardioplegia facilitated earlier sinus rhythm recovery.
Clinical Significance:
Saline-based mDN cardioplegia may be a viable alternative for canine MVR.
More Related Videos
Related Concept Videos
Mitral Stenosis III: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy

